阿尔法-同核素在前性痴呆症中的作用:叙述性审查
11st Department of Neurology, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Cells
|March 14, 2026
概括
阿尔法-同核素 (α-Syn) 通过与其他蛋白质联合聚合,显著加重前性痴呆症 (FTD). 针对多种蛋白质病理对于有效的FTD治疗至关重要.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 生物化学 生化学
背景情况:
- 前性痴呆症 (FTD) 通常根据tau或TDP-43蛋白聚合物进行分类.
- 阿尔法同核素 (α-Syn) 越来越被认为是FTD进展的关键因素.
- 涉及α-Syn的共同病理在FTD变体中很常见.
研究的目的:
- 对FTD中FTLD-synuclein和α-Syn共同病理学的当前文献进行审查.
- 了解α-Syn对疾病进展和异质性的影响.
- 评估诊断和治疗方面的影响.
主要方法:
- 临床,神经病理和生物化学研究的综合叙事综述.
- 专注于常见FTD亚型中的FTLD-synuclein和α-Syn共同病理.
- 对交叉播种机制的分析和生物标志物检测.
主要成果:
- α-Syn与tau和TDP-43共同聚合,加速神经退行和临床异质性.
- 二次α-Syn病理与FTD的快速认知衰退相关.
- 目前的生物标志物往往无法检测出这种蛋白重叠,从而影响临床试验的有效性.
结论:
- α-Syn是FTD中神经退行的一个重要,未被认可的驱动因素.
- 对于FTD,需要多个目标的治疗和诊断策略.
- 解决协同蛋白质聚合物的毒性至关重要,超越单一蛋白质方法.
相关概念视频
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Neural Regulation
44.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.0K
Amyloid Fibrils
12.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.6K
Amyloid Fibrils
6.9K
6.9K
Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K


